Publications 2004 [References 172–215]

172. Van Damme P, Burgess M. Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults. Vaccine 2004;22:305-8. [abstract]

173. Hull BP, McIntyre PB, Couzos S. Evaluation of immunisation coverage for Aboriginal and Torres Strait Islander children using the Australian Childhood Immunisation Register. Australian and New Zealand Journal of Public Health 2004;28:47-52. [full text]

174. Thiry N, Beutels P, Van Damme P, Van Doorslaer E. Economic evaluation of varicella vaccination programmes: a review of the literature [letter - authors' reply]. Pharmacoeconomics 2004;22(2):136-8. [no abstract available]

175. Yohannes K, Roche P, Blumer C, Spencer
J, Milton A, Bunn C, Gidding H, Kirk M, Della-Porta T. Australia's notifiable diseases status, 2002: Annual report of the National Notifiable Diseases Surveillance System Communicable Diseases Intelligence
2004;28:6-68. [full text]

176. McIntyre P. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases. Communicable Diseases Intelligence 2004;28:92-95.[full text]

177. Butler JRG, McIntyre P, MacIntyre CR, Gilmour R, Howarth AL, Sander B. The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Vaccine 2004;22:1138-49.[abstract]

178. Brotherton JML. Where to from here? [letter]. BMJ Rapid response, 8 Mar 2004. [full text]

179. Postma MJ, Bos JM, de Groot R, Luytjes W, Beutels P. Do costs of varicella justify routine infant vaccination? Pharmaco-economic and clinical considerations [editorial] European Journal of Health Economics 2004;5:54-7. [no abstract available]

180. Elliott E, McIntyre P, Ridley G, Morris A, Massie J, McEniery J, Knight G. A national study of infants hospitalized with pertussis in the acellular vaccine era. Pediatric Infectious Disease Journal 2004;23:246-52. [abstract]

181. Van de Beek D, de Gans J, McIntyre P, Prasad K. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infectious Diseases 2004;4:139-43. [abstract]

182. Poynten M, McIntyre PB, Mooi FR, Heuvelman KJ, Gilbert GL. Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiology and Infection 2004;132:185-93. [abstract]

183. McIntyre P, Wood N. What’s new in childhood immunisation? Medicine Today 2004;5:68-77. No abstract available.

184. Burgess MA, McIntyre PB. Vaccines -the new Australian best-practice schedule. Medical Journal
of Australia 2004;180:494-6. [fulltext]

185. Hethcote HW, Horby P, McIntyre P. Using computer simulations to compare pertussis vaccination strategies in Australia. Vaccine 2004;22:2181-91. [abstract]

186. Lawrence GL, MacIntyre CR, Hull BP, McIntyre PB. Effectiveness of the linkage of childcare and maternity payments to childhood immunisation. Vaccine 2004;22:2345-50. [abstract]

187. Brotherton JML. Internet is indeed useful source for patients with cancer [letter]. BMJ 2004;328:898. [full text]

188. Williams K, Hayen A, MacIntyre CR, Mellis C. Using evidence to inform decisions. In: Moyer VA, Elliott EJ (eds). Evidence-based pediatrics and child health. 2nd edition. London: BMJ Books; 2004. p. 161-6.

189. McIntyre P. Meningitis. In: Moyer VA, Elliott EJ (eds). Evidence-based pediatrics and child health. 2nd edition. London: BMJ Books; 2004. p. 285-91.

190. Beutels P, Viney RC. Comments on Prosser et al's approach to value disease reduction in children [letter]. Pediatrics 2004;114:1375. [full text]

191. Lawrence GL, Hull BP, MacIntyre CR, McIntyre PB. Reasons for incomplete immunisation among Australian children: a national survey of parents. Australian Family Physician 2004;33:568-71.[abstract]

192. Scuffham P, McIntyre P. Pertussis vaccination strategies for neonates - an exploratory cost-effectiveness analysis. Vaccine 2004;22:2953-64. [abstract]

193. O’Sullivan BG, Gidding HF, Law M, Kaldor JM, Gilbert GL, Dore GJ. Estimates of chronic hepatitis B virus infection in Australia, 2000. Australian and New Zealand Journal of Public Health 2004;28:212-6. [full text]

194. De Graeve D, Beutels P. Economic aspects of pneumococcal pneumonia: a review of the literature. Pharmacoeconomics 2004;22:719-40. [abstract]

195. Menzies R, McIntyre P, Beard F. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 1999 to 2002. Communicable Diseases Intelligence 2004;28(Suppl 1):S1-S45. [full text]

196. Hull BP, McIntyre PB. What do we know about 7vPCV coverage in Aboriginal and Torres Strait Islander children? Communicable Diseases Intelligence 2004;28:238-43. full text]

197. Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Communicable Diseases Intelligence 2004;28:244-8. [full text]

198. Brotherton JML, McIntyre PB. Planning for human papillomavirus vaccines in Australia. Report of a research group meeting. Communicable Diseases Intelligence 2004;28:249-54. [full text]

199. Postma MJ, Beutels P, Bos JM, Schilthuis H, van den Hoek JAR. Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands). Vaccine 2004;22:1862-7. [abstract]

200. Beutels P. Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination. Vaccine 2004;22:3312-22. [abstract]

201. McIntyre P, Wood N. Does universal hepatitis B vaccination at birth have a negative impact on breastfeeding?Australian Midwifery 2004;17:8-9. [no abstract available]

202. McIntyre P. Festschrift for Margaret Burgess – Foreword. Expert Review of Vaccines 2004;3:337.[no abstract available]

203. McIntyre P. Vaccine strategies for prevention of neonatal pertussis. Expert Review of Vaccines 2004;3:375-8. [abstract]

204. Leask J, Williams A, McIntyre P, O'Dea D. Are General Practice Registrars prepared for immunisation? A cross sectional survey. Australian Family Physician 2004;33:665-7. [abstract]

205. Lawrence GL, Boyd I, McIntyre P, Isaacs D. Surveillance of adverse events following immunisation: Australia 2002 to 2003. Communicable Diseases Intelligence 2004;28:324-38. [full text]

206. Brotherton JML. Festschrift for Margaret Burgess. Communicable Diseases Intelligence 2004;28:349-55. [full text]

207. Andrews RM, Counahan ML, Hogg GG, McIntyre PB. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria,
Vaccine 2004;23:132-8. [abstract]

208. Cheuvart B, Burgess M, Zepp F, Mertsola, Wolter J, Schuerman L. Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine 2004;23:336-42. [abstract]

209. McIntyre PB, Turnbull FM, Egan A, Burgess MA, Wolter JM, Schuerman LM. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine 2004;23:380-5. [abstract]

210. Ackermann D, Chapman S, Leask J. Media coverage of anthrax vaccination refusal by Australian Defence Force personnel. Vaccine 2004;23:411-7. [abstract]

211. MacIntyre CR. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: A prospective study [letter]. Neurology Published online 11 November 2004. [no abstract available]

212. Lawrence G, Boyd I. Surveillance of adverse events following immunisation for children aged less than 7 years, 1 January to 30 June 2004. Communicable Diseases Intelligence 2004;28:490-2.[full text]

213. Milne BG, Williams S, May MLA, Kesson AM, Gillis J, Burgess MA. Influenza A associated morbidity and mortality in a paediatric intensive care unit. Communicable Diseases Intelligence 2004;28:504-9 [full text]

214. Amin J, Gidding HF, Gilbert GL, Backhouse J, Kaldor JM, Dore GJ, Burgess MA. Hepatitis C prevalence - a nationwide serosurvey. Communicable Diseases Intelligence 2004;28:517-21. [full text]

215. Brotherton J, McIntyre P, Puech M, Wang H, Gidding H, Hull B, Lawrence G, MacIntyre R, Wood N, Armstrong D. Vaccine preventable diseases and vaccination coverage in Australia, 2001 to 2002. Communicable Diseases Intelligence 2004;28 Suppl 2:i-S116. [full text]